Estrella Immunopharma (ESLA) Competitors $0.90 +0.04 (+4.37%) Closing price 08/15/2025 03:20 PM EasternExtended Trading$0.88 -0.02 (-2.56%) As of 08/15/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA vs. TNYA, AVTX, SCLX, GNLX, ALTS, IOBT, TARA, IMRX, LIMN, and SAVAShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Tenaya Therapeutics (TNYA), Avalo Therapeutics (AVTX), Scilex (SCLX), Genelux (GNLX), ALT5 Sigma (ALTS), IO Biotech (IOBT), Protara Therapeutics (TARA), Immuneering (IMRX), Liminatus Pharma (LIMN), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Its Competitors Tenaya Therapeutics Avalo Therapeutics Scilex Genelux ALT5 Sigma IO Biotech Protara Therapeutics Immuneering Liminatus Pharma Cassava Sciences Tenaya Therapeutics (NASDAQ:TNYA) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations. Does the media refer more to TNYA or ESLA? In the previous week, Tenaya Therapeutics had 10 more articles in the media than Estrella Immunopharma. MarketBeat recorded 14 mentions for Tenaya Therapeutics and 4 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.81 beat Tenaya Therapeutics' score of 0.39 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Estrella Immunopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer TNYA or ESLA? Tenaya Therapeutics presently has a consensus price target of $6.25, suggesting a potential upside of 438.79%. Estrella Immunopharma has a consensus price target of $16.00, suggesting a potential upside of 1,681.74%. Given Estrella Immunopharma's higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Tenaya Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, TNYA or ESLA? Estrella Immunopharma is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenaya TherapeuticsN/AN/A-$111.13M-$0.96-1.21Estrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.45 Do institutionals and insiders hold more shares of TNYA or ESLA? 90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 48.7% of Tenaya Therapeutics shares are owned by company insiders. Comparatively, 55.1% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is TNYA or ESLA more profitable? Tenaya Therapeutics' return on equity of -93.83% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Tenaya TherapeuticsN/A -93.83% -75.66% Estrella Immunopharma N/A -1,132.38%-358.54% Which has more volatility and risk, TNYA or ESLA? Tenaya Therapeutics has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. SummaryTenaya Therapeutics beats Estrella Immunopharma on 7 of the 12 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.89M$3.09B$5.66B$9.82BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-3.4520.3830.5825.12Price / SalesN/A356.76462.42114.82Price / CashN/A42.3037.4059.05Price / Book-5.618.659.096.18Net Income-$7.31M-$54.65M$3.25B$264.89M7 Day Performance9.11%6.58%7.32%4.18%1 Month Performance6.30%7.54%5.41%1.99%1 Year Performance-36.31%13.73%30.66%24.22% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma3.0309 of 5 stars$0.90+4.4%$16.00+1,681.7%-36.3%$31.89MN/A-3.45N/ANews CoverageAnalyst ForecastGap UpTNYATenaya Therapeutics3.0478 of 5 stars$0.76+11.1%$6.25+725.6%-61.3%$123.38MN/A-0.79110AVTXAvalo Therapeutics3.4979 of 5 stars$9.36+3.9%$30.00+220.5%-2.6%$123.08M$440K0.0040News CoverageAnalyst ForecastShort Interest ↓Gap UpSCLXScilex2.2007 of 5 stars$17.67+11.7%$455.00+2,475.0%-58.3%$122.81M$56.59M-0.6180News CoverageEarnings ReportHigh Trading VolumeGNLXGenelux1.762 of 5 stars$3.19-2.7%$17.75+456.4%+67.1%$120.49M$10K-3.7110News CoveragePositive NewsAnalyst RevisionALTSALT5 Sigma0.6429 of 5 stars$5.96-9.7%N/A+228.2%$120.05M$18.05M0.00170News CoverageAnalyst DowngradeOptions VolumeHigh Trading VolumeIOBTIO Biotech3.0263 of 5 stars$1.31+24.8%$8.67+561.6%+60.0%$119.24MN/A-0.8830News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap UpHigh Trading VolumeTARAProtara Therapeutics2.1774 of 5 stars$3.07-1.0%$19.60+538.4%+47.8%$118.44MN/A-1.7830News CoverageEarnings ReportAnalyst RevisionIMRXImmuneering3.7359 of 5 stars$3.25+1.2%$13.25+307.7%+248.1%$116.97M$320K-1.6660News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastLIMNLiminatus PharmaN/A$4.35-2.9%N/AN/A$113.14MN/A0.00N/APositive NewsSAVACassava Sciences2.0977 of 5 stars$2.32+3.1%$2.00-13.8%-91.8%$112.08MN/A-1.5530News CoverageEarnings Report Related Companies and Tools Related Companies Tenaya Therapeutics Competitors Avalo Therapeutics Competitors Scilex Competitors Genelux Competitors ALT5 Sigma Competitors IO Biotech Competitors Protara Therapeutics Competitors Immuneering Competitors Liminatus Pharma Competitors Cassava Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLA) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.